Genetics of Parkinson's disease and biochemical studies of implicated gene products: Commentary

Current Opinion in Cell Biology

Volumn 14, Issue 5, 2002, Pages 653-660

  Lansbury Jr , Peter T ^a   Brice, Alexis ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BETA SYNUCLEIN; DJ 1 PROTEIN; GENE PRODUCT; HYDROLASE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MESSENGER RNA; PARKIN; PROTEIN PARK5; PROTEIN PARK6; PROTEIN UCH L1; UBIQUITIN C; UNCLASSIFIED DRUG;

CHROMOSOME; CLINICAL FEATURE; DISEASE COURSE; FAMILIAL DISEASE; GENE LOCUS; GENE MAPPING; GENE MUTATION; GENETIC LINKAGE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN GENOME; LEWY BODY; MEDICAL GENETICS; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 0036775723     PISSN: 09550674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-0674(02)00377-0     Document Type: Note

References (80)

1. Dawson T.M. New animal models for Parkinson's disease. Cell. 101:2000;115-118.
2. Parkinson Study Group . Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. J Am Med Assoc. 284:2000;1931-1938.
3. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
4. Bostantjopoulou S., Katsarou Z., Papadimitriou A., Veletza V., Hatzigeorgiou G., Lees A. Clinical features of parkinsonian patients with the alpha-synuclein (G209A) mutation. Mov Disord. 16:2001;1007-1013.
5. Papapetropoulos S., Paschalis C., Athanassiadou A., Papadimitriou A., Ellul J., Polymeropoulos M.H., Papapetropoulos T. Clinical phenotype in patients with alpha-synuclein Parkinson's disease living in Greece in comparison with patients with sporadic Parkinson's disease. J Neurol Neurosurg Psychiatry. 70:2001;662-665.
6. Spira P.J., Sharpe D.M., Halliday G., Cavanagh J., Nicholson G.A. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol. 49:2001;313-319. Description of clinical and neuropathological features highly atypical of PD in an Australian family with the A53T mutation of the α-synuclein gene.
7. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 18:1998;106-108.
8. Khan N., Graham E., Dixon P., Morris C., Mander A., Clayton D., Vaughan J., Quinn N., Lees A., Daniel S., et al. Parkinson's disease is not associated with the combined alpha-synuclein/apolipoprotein E susceptibility genotype. Ann Neurol. 49:2001;665-668.
9. Izumi Y., Morino H., Oda M., Maruyama H., Udaka F., Kameyama M., Nakamura S., Kawakami H. Genetic studies in Parkinson's disease with an alpha-synuclein/NACP gene polymorphism in Japan. Neurosci Lett. 300:2001;125-127.
10. Farrer M., Maraganore D.M., Lockhart P., Singleton A., Lesnick T.G., de Andrade M., West A., de Silva R., Hardy J., Hernandez D. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet. 10:2001;1847-1851.
11. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA. 97:2000;571-576.
12. Uversky V.N., Lee H.J., Li J., Fink A.L., Lee S.J. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem. 276:2001;43495-43498.
13. Uversky V.N., Li J., Fink A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem. 276:2001;10737-10744.
14. Eliezer D., Kutluay E., Bussell R. Jr, Browne G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol. 307:2001;1061-1073. Using NMR, Eliezer et al. find that free monomeric wild-type α-synuclein exists in a mostly unfolded state in solution but shows a region with a preference for helical conformations that may be important for the known propensity of α-synuclein to aggregate into fibrils.
15. Volles M.J., Lee S.J., Rochet J.C., Shtilerman M.D., Ding T.T., Kessler J.C., Lansbury P.T. Jr. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry. 40:2001;7812-7819. One of us (PL) has demonstrated that protofibrils are rich in β-sheet structure and bind membrane surfaces much more avidly than either monomer or fibril. Furthermore, protofibrils permeabilize synthetic vesicles and lead to destruction of vesicular membranes, as demonstrated by atomic force microscopy.
16. Giasson B.I., Murray I.V., Trojanowski J.Q., Lee V.M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem. 276:2001;2380-2386.
17. Uversky V.N., Li J., Fink A.L. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem. 276:2001;44284-44296.
18. Uversky V.N., Li J., Fink A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett. 500:2001;105-108.
19. Sharon R., Goldberg M.S., Bar-Josef I., Betensky R.A., Shen J., Selkoe D.J. alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci USA. 98:2001;9110-9115. This paper provides data to support the idea that α-synuclein is a fatty acid binding protein, and is associated with membrane compartments in cells. This possible function is consistent with the localization of α-synuclein to plasma membranes, which is disrupted by the A30P mutation.
20. Lee F.J., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15:2001;916-926.
21. Cole N.B., Murphy D.D., Grider T., Rueter S., Brasaemle D., Nussbaum R.L. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem. 277:2002;6344-6352.
22. Narayanan V., Scarlata S. Membrane binding and self-association of alpha-synucleins. Biochemistry. 40:2001;9927-9934.
23. Perrin R.J., Woods W.S., Clayton D.F., George J.M. Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem. 276:2001;41958-41962.
24. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:2001;263-269. Shimura et al. identify a protein complex in normal human brain that includes parkin as the E3 ubiquitin ligase (UbcH7) as its associated E2 ubiquitin conjugating enzyme, in addition to a new 22kD glycosylated form of α-synuclein (alphaSp22) as its substrate. They report that, in contrast to normal parkin, mutant parkin associated with autosomal recessive PD fails to bind alphaSp22. Furthermore, in an in vitro ubiquitination assay, alphaSp22 is reported to be modified by normal but not the mutant parkin into a high molecular weight poly-ubiquitinated species. They further report that alphaSp22 accumulates in a non-ubiquitinated form in the parkin-deficient PD brains. The authors conclude that alphaSp22 is a substrate for parkin's ubiquitin ligase activity in normal human brain and that loss of parkin function causes pathological alphaSp22 accumulation.
25. Nakamura K., Bindokas V.P., Kowlessur D., Elas M., Milstien S., Marks J.D., Halpern H.J., Kang U.J. Tetrahydrobiopterin scavenges superoxide in dopaminergic neurons. J Biol Chem. 276:2001;34402-34407.
26. Ellis C.E., Schwartzberg P.L., Grider T.L., Fink D.W., Nussbaum R.L. alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J Biol Chem. 276:2001;3879-3884.
27. Przedborski S., Chen Q., Vila M., Giasson B.I., Djaldatti R., Vukosavic S., Souza J.M., Jackson-Lewis V.V., Lee V.M., Ischiropoulos H. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Neurochem. 76:2001;637-640.
28. Conway K.A., Rochet J.C., Bieganski R.M., Lansbury P.T. Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 294:2001;1346-1349. One of us (PL) has shown that an in vitro incubation of α-synuclein with dopamine and structurally related catecholamines, results in a covalently modified protein adduct (DA-α-synuclein); furthermore, the DA-α-synuclein adduct was shown to selectively inhibit protofibril → fibril conversion, resulting in accumulation of the α-synuclein protofibril, a presumably neurotoxic species. This finding suggests that cytosolic dopamine under oxidative stress conditions leads to accumulation of a toxic protofibrillar intermediate(s), and provides an explanation for the dopaminergic selectivity of α-synuclein associated neurotoxicity in PD.
29. Rockenstein E., Hansen L.A., Mallory M., Trojanowski J.Q., Galasko D., Masliah E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 914:2001;48-56.
30. Hashimoto M., Rockenstein E., Mante M., Mallory M., Masliah E. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron. 32:2001;213-223.
31. Payton J.E., Perrin R.J., Clayton D.F., George J.M. Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. Brain Res Mol Brain Res. 95:2001;138-145.
32. Kawamata H., McLean P.J., Sharma N., Hyman B.T. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations. J Neurochem. 77:2001;929-934.
33. Lee F.J., Liu F., Pristupa Z.B., Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15:2001;916-926.
34. Kimura M., Matsushita S., Arai H., Takeda A., Higuchi S. No evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease. Ann Neurol. 49:2001;276-277.
35. Farrer M., Destee A., Levecque C., Singleton A., Engelender S., Becquet E., Mouroux V., Richard F., Defebvre L., Crook R., et al. Genetic analysis of synphilin-1 in familial Parkinson's disease. Neurobiol Dis. 8:2001;317-323.
36. Cole R.N., Hart G.W. Cytosolic O-glycosylation is abundant in nerve terminals. J Neurochem. 79:2001;1080-1089. This paper demonstrates that many synaptosomal protesin are O-glycosylated, including UCH-L1 and β-synuclein, proteins that are discussed above.
37. Stefanis L., Larsen K.E., Rideout H.J., Sulzer D., Greene L.A. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci. 21:2001;9549-9560.
38. Touchman J.W., Dehejia A., Chiba-Falek O., Cabin D.E., Schwartz J.R., Orrison B.M., Polymeropoulos M.H., Nussbaum R.L. Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Res. 11:2001;78-86.
39. Lee H.J., Shin S.Y., Choi C., Lee Y.H., Lee S.J. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem. 277:2002;5411-5417.
40. Rideout H.J., Larsen K.E., Sulzer D., Stefanis L. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem. 78:2001;899-908.
41. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A., V L.D., Dawson T.M., Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet. 10:2001;919-926.
42. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett. 297:2001;191-194.
43. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., Harhangi B.S., Meco G., Denefle P., Wood N.W., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med. 342:2000;1560-1567.
44. Klein C., Pramstaller P.P., Kis B., Page C.C., Kann M., Leung J., Woodward H., Castellan C.C., Scherer M., Vieregge P., et al. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol. 48:2000;65-71.
45. Oliveri R.L., Zappia M., Annesi G., Bosco D., Annesi F., Spadafora P., Pasqua A.A., Tomaino C., Nicoletti G., Pirritano D., et al. The parkin gene is not involved in late-onset Parkinson's disease. Neurology. 57:2001;359-362.
46. Hedrich K., Kann M., Lanthaler A.J., Dalski A., Eskelson C., Landt O., Schwinger E., Vieregge P., Lang A.E., Breakefield X.O., et al. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum Mol Genet. 10:2001;1649-1656.
47. Terreni L., Calabrese E., Calella A.M., Forloni G., Mariani C. New mutation (R42P) of the parkin gene in the ubiquitinlike domain associated with parkinsonism. Neurology. 56:2001;463-466.
48. West A, Périquet M, Lincoln S, Lücking CB, Nicholl D, Bonifati V, Rawal N, Gasser T, Lohmann E, Deleuze JF, et al: The complex relationship between parkin mutations and Parkinson's disease. Am J Hum Genet 2002, in press.
49. Periquet M., Lucking C., Vaughan J., Bonifati V., Durr A., De Michele G., Horstink M., Farrer M., Illarioshkin S.N., Pollak P., et al. Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. Am J Hum Genet. 68:2001;617-626. Demonstration of a founder effect accounting for several point mutations but not for exon rearrangements detected in families of various geographical origins.
50. Nisipeanu P., Inzelberg R., Abo Mouch S., Carasso R.L., Blumen S.C., Zhang J., Matsumine H., Hattori N., Mizuno Y. Parkin gene causing benign autosomal recessive juvenile parkinsonism. Neurology. 56:2001;1573-1575.
51. Kuroda Y., Mitsui T., Akaike M., Azuma H., Matsumoto T. Homozygous deletion mutation of the parkin gene in patients with atypical parkinsonism. J Neurol Neurosurg Psychiatry. 71:2001;231-234.
52. van de Warrenburg B.P., Lammens M., Lucking C.B., Denefle P., Wesseling P., Booij J., Praamstra P., Quinn N., Brice A., Horstink M.W. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology. 56:2001;555-557.
53. Portman A.T., Giladi N., Leenders K.L., Maguire P., Veenma-van der Duin L., Swart J., Pruim J., Simon E.S., Hassin-Baer S., Korczyn A.D. The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations. Neurology. 56:2001;1759-1762.
54. Hilker R., Klein C., Ghaemi M., Kis B., Strotmann T., Ozelius L.J., Lenz O., Vieregge P., Herholz K., Heiss W.D., et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol. 49:2001;367-376.
55. Farrer M., Chan P., Chen R., Tan L., Lincoln S., Hernandez D., Forno L., Gwinn-Hardy K., Petrucelli L., Hussey J., et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol. 50:2001;293-300. The authors report the first neuropathological case with parkin mutations and presence of Lewy bodies.
56. Maruyama M., Ikeuchi T., Saito M., Ishikawa A., Yuasa T., Tanaka H., Hayashi S., Wakabayashi K., Takahashi H., Tsuji S. Novel mutations, pseudo-dominant inheritance, and possible familial affects in patients with autosomal recessive juvenile parkinsonism. Ann Neurol. 48:2000;245-250.
57. Bonifati V., De Michele G., Lucking C.B., Durr A., Fabrizio E., Ambrosio G., Vanacore N., De Mari M., Marconi R., Capus L., et al. The parkin gene and its phenotype. Italian PD Genetics Study Group, French PD Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Neurol Sci. 22:2001;51-52.
58. Lücking C.B., Bonifati V., Periquet M., Vanacore N., Brice A., Meco G. Pseudo-dominant inheritance and exon 2 triplication in a family with parkin gene mutations. Neurology. 57:2001;924-927.
59. Corti O., Brice A. Parkin and Parkinson's: more than homonymy? Ann Neurol. 50:2001;283-285.
60. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 105:2001;891-902. Imai et al. demonstrate that the unfolded Pael receptor is a substrate of Parkin, and that the accumulation of this receptor may result in selective neuronal death in AR-JP. The linkage of parkin to a protein that is involved in the unfolded protein response suggests that protein (α-synuclein) misfolding and aggregation may be pathogenic (see Fig. 1 ).
61. Imai Y., Soda M., Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem. 275:2000;35661-35664.
62. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., Dawson T.M. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA. 97:2000;13354-13359.
63. Fallon L., Moreau F., Croft B.G., Labib N., Gu W.J., Fon E.A. Parkin and CASK/LIN-2 associate via a PDZ-mediated interaction and are co-localized in lipid rafts and postsynaptic densities in brain. J Biol Chem. 277:2002;486-491.
64. Briggs M.D., Mortier G.R., Cole W.G., King L.M., Golik S.S., Bonaventure J., Nuytinck L., De Paepe A., Leroy J.G., Biesecker L., et al. Diverse mutations in the gene for cartilage oligomeric matrix protein in the pseudoachondroplasia-multiple epiphyseal dysplasia disease spectrum. Am J Hum Genet. 62:1998;311-319.
65. Maraganore D.M., Farrer M.J., Hardy J.A., Lincoln S.J., McDonnell S.K., Rocca W.A. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology. 53:1999;1858-1860.
66. Satoh J., Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J Neurol Sci. 189:2001;113-117.
67. Momose Y., Murata M., Kobayashi K., Tachikawa M., Nakabayashi Y., Kanazawa I., Toda T. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol. 51:2002;133-136.
68. Valente E.M., Bentivoglio A.R., Dixon P.H., Ferraris A., Ialongo T., Frontali M., Albanese A., Wood N.W. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet. 68:2001;895-900. Mapping of PARK6 to chromosome 1p35-p36 in a Sicilian family with autosomal recessive early-onset parkinsonism.
69. Bentivoglio A.R., Cortelli P., Valente E.M., Ialongo T., Ferraris A., Elia A., Montagna P., Albanese A. Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Mov Disord. 16:2001;999-1006.
70. Valente E.M., Brancati F., Ferraris A., Graham E.A., Davis M.B., Breteler M.M., Gasser T., Bonifati V., Bentivoglio A.R., De Michele G., et al. PARK6-linked parkinsonism occurs in several European families. Ann Neurol. 51:2002;14-18.
71. van Duijn C.M., Dekker M.C., Bonifati V., Galjaard R.J., Houwing-Duistermaat J.J., Snijders P.J., Testers L., Breedveld G.J., Horstink M., Sandkuijl L.A., et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet. 69:2001;629-634. This study of an isolate from the south-west of the Netherlands enabled the gene for a new form of autosomal recessive early-onset parkinsonism to be mapped to chromosome 1p36.
72. Bonifati V., Breedveld G.J., Squitieri F., Vanacore N., Brustenghi P., Harhangi B.S., Montagna P., Cannella M., Fabbrini G., Rizzu P., et al. Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset. Ann Neurol. 51:2002;253-256.
73. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuki S., Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol. 51:2002;296-301. The study of a large Japanese family with autosomal-dominant parkinsonism permitting the mapping of PARK8 to chromosome 12p11.2-q13.1. Patients present with dopa-responsive parkinsonism, caused by pure nigral degeneration without Lewy bodies.
74. DeStefano A.L., Golbe L.I., Mark M.H., Lazzarini A.M., Maher N.E., Saint-Hilaire M., Feldman R.G., Guttman M., Watts R.L., Suchowersky O., et al. Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology. 57:2001;1124-1126.
75. Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., Lyons K., Pahwa R., Stern M.B., Colcher A., Hiner B.C., et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. J Am Med Assoc. 286:2001;2239-2244.
76. Pastor P., Pastor E., Carnero C., Vela R., Garcia T., Amer G., Tolosa E., Oliva R. Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene. Ann Neurol. 49:2001;263-267.
77. Golbe L.I., Lazzarini A.M., Spychala J.R., Johnson W.G., Stenroos E.S., Mark M.H., Sage J.I. The tau A0 allele in Parkinson's disease. Mov Disord. 16:2001;442-447.
78. Maraganore D.M., Hernandez D.G., Singleton A.B., Farrer M.J., McDonnell S.K., Hutton M.L., Hardy J.A., Rocca W.A. Case-Control study of the extended tau gene haplotype in Parkinson's disease. Ann Neurol. 50:2001;658-661.
79. Spillantini M.G., Goedert M. Tau and Parkinson disease. J Am Med Assoc. 286:2001;2324-2326.
80. Hicks A., Petursson H., Jonsson T., et al. A susceptibility gene to late-onset idiopathic Parkinson's disease successfully mapped [Abstract 123]. Am J Hum Genet. 69:2001;A200.